Introduction
Evidence that the immune system plays a role in the control of chronic myeloid leukemia (CML) is provided by the fact that CML responds to immune-mediated therapies such as interferon alpha (IFN-a), allogeneic stem cell transplantation (ASCT) and donor lymphocyte infusion. 1, 2 Upon treatment with IFN-a and ASCT, the emergence of CD8 þ T cells directed against tumor antigens like proteinase 3 correlates to cytogenetic remission. 3, 4 In contrast, the lack of such T cells at diagnosis suggests the existence of tumor escape mechanisms from immune surveillance such as the production of immunosuppressive factors and a dominant Th2-type of immunity. 3 Dendritic cells (DC) are central to the initiation of protective Tcell immunity against tumors. In humans, the detection of circulating blood DC (BDC) is classically based on a series of immunophenotypic criteria such as the absence of lineage (Lin)-specific markers, the presence of HLA-DR and the differential expression of the b-integrin CD11c and of the IL-3Ra CD123. Myeloid DC (MDC) bright PDC. BDCA-4 is identical to neuropilin-1 (NRP-1), 6 a multifunctional receptor for ligands from structurally distinct families. On endothelial cells and tumor cells, NRP-1 binds several VEGF family members and enhances VEGF receptor-2 (VEGF-R2)-mediated biological functions. 7 Recently, NRP-1 was shown to be involved in the DC-T-cell synapse through homophilic interactions during the primary immune response. 8 DC are important targets for tumor escape mechanisms from immune control in cancer patients. Many factors released by cancer cells have the capacity to inhibit DC production or function. 9 In CML, VEGF is overexpressed in the plasma and bone marrow of untreated patients. 10 In addition to tumor angiogenesis promotion, VEGF inhibits DC differentiation, 11, 12 but little is known about VEGF-dependent blockade of DC production in patients. In CML cell lines, VEGF secretion has recently been assigned to bcr-abl tyrosine kinase activity. 13 However, the kinetics of VEGF normalization in patients under imatinib mesylate (IM), the tyrosine kinase inhibitor now given as front-line therapy, remain to be determined.
In this study, we asked whether VEGF overproduction was associated with BDC deficiencies in a cohort of 30 chronic phase (CP) CML patients prior treatment. We next evaluated in a prospective fashion, the in vivo impact of IM on plasmatic VEGF, BDC populations and Th-cell responses.
Materials and methods

Patients and healthy donors (HD)
CP CML patients above 18 years eligible for the study had to have been previously untreated except for hydroxyurea. Patients with a history that could interfere with the study (malignant solid tumors, chronic viral infection and immune disorders) were excluded. Peripheral blood was obtained after informed consent before IM therapy (400 mg daily) and every 3 months thereafter (up to 12 months). Our protocol was approved by the Institutional Review Board (St Louis Hospital, Paris, France). Response to IM was monitored with blood studies including cell counts and measurement of bcr-abl transcripts by RQ-PCR every 3 months and marrow studies including cytology, cytogenetics and measurement of bcr-abl every 6 months. Patients characteristics are summarized in 
BDC quantification and immunophenotyping
Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density-gradient centrifugation (Eurobio). PBMC were analyzed by two-color staining on a FACScan cytometer (CellQuest, Becton-Dickinson). MoAb directed against the following antigens and their corresponding isotype controls were used: CD15 (HI98), CD19 (HIB19), CD11c (B-ly6), HLA-DR (G46-6) (Pharmingen); CD123 (IL-3R-a, 9F5), lineage cocktail 1 (CD3, CD14, CD16, CD19, CD20, CD56) (Becton Dickinson); BDCA-1/CD1c, CD14, BDCA-2, BDCA-3, BDCA-4/ NRP-1 (Miltenyi Biotec). PDC were identified as BDCA-2 þ / CD123 bright cells and were Lin À , CD11c À , and HLA-DR þ as described. 5 Since BDCA-1 can be found on a subset of B cells, BDCA-1 þ MDC were detected as BDCA-1 þ /CD19 À . Because BDCA-3 is highly expressed on BDCA-3 þ MDC and at intermediate levels on BDCA-1 þ MDC, PDC and monocytes, BDCA-3 þ MDC were detected as BDCA-3 high /CD14 À . 5 Granulocytic precursors account for increased PBMC counts in CML. Thus, to accurately compare BDC between HD and patients, data were expressed as a percentage of PBMC after exclusion of granulocytic precursors based on forward and sideward light scatter properties and CD15 staining.
Circulating VEGF measurement
Plasma was collected using EDTA as anticoagulant, aliquoted and stored at À801C until analysis. VEGF was detected with the Quantikine ELISA kit (R&D systems, sensitivity 9 pg/ml) in patients before and after IM treatment and in 13 HD.
Allogeneic mixed lymphocyte reaction and T helper (Th)-cell polarization
PDC from HD were purified with the BDCA-4 Cell Isolation Kit (Miltenyi Biotec) as recommended by the manufacturer. Recovered PDC were more than 90% pure. Naive CD4 þ T cells were isolated from HD using the human CD4 þ / CD45RO
À naive T-cell subset column kit (R&D systems) according to the manufacturer's instructions. Purified PDC were plated at 50 000/well in 96-well flat-bottom plates with 10 ng/ml IL-3 for 48 h. To study the impact of VEGF on Th-cell polarization, PDC were harvested and cultured at 10 000/well with 50 000 allogeneic CD4 þ /CD45RO À T cells in 96-well Ubottom-plates with or without VEGF 165 (50 ng/ml, R&D systems). CD4
þ T cells were collected on day 7 and stimulated for 4 h with PMA (20 ng/ml) and calcium ionophore (500 ng/ml) in the presence of brefeldin A (5 mg/ml) (Sigma). T cells were fixed with 4% paraformaldehyde, permeabilized with saponin and stained with FITC-anti-IFN-g and PE-anti-IL-4 MoAb (Pharmingen).
To study Th-cell polarization in CML, PBMC were plated at 10 6 /ml in 24-well plates, stimulated with PMA and calcium ionophore in the presence of brefeldin A, fixed in paraformaldehyde and permeabilized as above. PBMC were stained with a Cychrome-conjugated anti-CD4 MoAb (Becton Dickinson) and with FITC-anti-IFN-g and PE-anti-IL-4 MoAb. Polarization towards Th1 and Th2 subsets was measured by flow cytometry after gating on the CD4 þ T-cell compartment. Results were expressed as a ratio of percentage of Th1 (IFN-g þ /IL-4 À ) and Th2
Statistical analysis
Box plots were used to show the median and 10th, 25th, 75th and 90th percentiles for each group. Comparisons between groups were performed using Fisher's exact test for binary variables and Mann-Whitney test for continuous variables.
Results
Low BDC subsets in CP CML and partial recovery upon IM treatment PDC and MDC were studied before IM treatment and compared with those from HD. In HD, median PDC, BDCA-1 þ and BDCA-3 þ MDC, respectively, represented 0.45% (range, 0.22-1.06%), 0.52% (range, 0.21-1.19%) and 0.1% (range, 0.03-0.24%) of PBMC ( Figure 1 ). In contrast, CML patients showed a dramatic decrease in BDC among normal PBMC with 0.08% PDC (range, 0-0.42%), 0.13% BDCA-1 þ MDC (range 0-0.69%) and 0.01% BDCA-3 þ MDC (range, 0-0.12%) (Po0.0001) (Figure 1 ). After 3 months of IM administration, a significant increase in PDC, BDCA-1 þ MDC and BDCA-3 þ MDC was observed and this increase was sustained until month 6 of treatment (Figure 2a-c) . At 6 months, a plateau was reached and BDC did not further increase (Figure 2d ). The rate of BDC achieved in treated patients remained significantly lower than that found in HD (P ¼ 0.008, 0.009 and 0.002 for PDC, BDCA1 þ MDC and BDCA-3 þ MDC, respectively). Since none of the patients of our study were in complete molecular response, we studied four additional patients with undetectable bcr-abl transcripts after 12 months (n ¼ 1), 15 months (n ¼ 2) and 18 months (n ¼ 1) of IM treatment. We found that median BDC rates remained inferior to HD values with 0.29% PDC (0.13-0.59%), 0.32% BDCA-1 þ MDC (0.26-0.35%) and 0.03% BDCA-3 þ MDC (0.02-0.04%) (not shown).
High plasmatic VEGF associates with low BDC and is rapidly corrected by IM Given the ability of VEGF to compromise human DC development from CD34 þ precursors, 11 the possibility that 
Blood dendritic cells in CML
N Boissel et al pathologically enhanced VEGF production may result in low BDC in CML was explored. Median plasmatic VEGF was significantly higher (Po0.0001) in patients prior treatment (median, 1676 pg/ml; range, 300-8630 pg/ml) than that in HD (median, 406 pg/ml; range, 93-612 pg/ml) (Figure 3a) . In addition, patients with circulating PDC, BDCA-1 þ MDC and BDCA-3 þ MDC rates below median levels had significantly higher circulating VEGF (P ¼ 0.002, 0.02 and 0.04, respectively) than patients with DC rates above median levels (Figure 3b) . After 3 months of IM administration, VEGF concentrations returned within physiological limits in all patients (median, 380 pg/ml; range, 29-699 pg/ml) (Figure 3a) . The relationship between high VEGF and low DC rates led us to study the expression of the VEGF-coreceptor BDCA-4 on PDC. In HD, PDC homogeneously expressed high levels of BDCA-4 ( Figure 3c ). In contrast, 44% of CML patients showed heterogeneous expression of BDCA-4, BDCA-4 À cells representing 5-66% of total PDC (Figure 3c ). After 3 months of IM administration, BDCA-4 À DC disappeared (Figure 3c ) except in two patients without a cytogenetic response (not shown).
High VEGF shifts PDC-driven T-cell polarization towards Th2 and associates with low Th1/Th2 ratio in CP CML
The above findings led us to explore VEGF impact on PDC function. Since purification of PDC from CML patients at diagnosis was hampered by their scarcity, we used PDC from HD to stimulate allogeneic naive CD4 þ T cells. In the presence of VEGF, PDC displayed a 40% decreased capacity to polarize CD4 þ T cells towards Th1-type immunity (IFN-g þ /IL-4 À ), while Th2-type responses (IFN-g À /IL-4 þ ) showed a 35% increase thereby shifting the Th1/Th2 balance towards Th2 (Figure 4a ). These results were consistent with the Th1/Th2 profiles in CML patients. Prior treatment, CD4
þ T cells showed a compromised Th1 cytokine production and an increase in Th2 cells with a median Th1/Th2 ratio at 3.4 (range, 0.2-8.7) while in HD, median Th1/Th2 ratio was significantly higher (median, 24.9, range, 13.8-42) (P ¼ 0.01) (Figure 4b ). Patients with Th1/ Th2 ratio below median levels had significantly higher circulating VEGF (P ¼ 0.02) than those with Th1/Th2 ratio above median levels (Figure 4c ). After 6 months of IM administration, Th1/Th2 ratio significantly increased (median 6.1, range 19.5) (P ¼ 0.02) but did not return to values found in HD (Figure 4b) .
Discussion
Despite the sensitivity of leukemic cells to immune attack by T cells, efficient antitumor responses are lacking in CML. As DC are critical regulators of cellular immunity, their characterization during the course of the disease may yield important informations on how CML escapes from immune control. The discovery of novel markers for fresh peripheral BDC enabled us to directly characterize PDC and MDC in CML. Although Figure 3 High plasmatic VEGF is associated with BDC abnormalities. (a) Plasmatic VEGF in HD (n ¼ 13), patients at diagnosis (diag., n ¼ 30) and after 3 months of IM (IM/M3, n ¼ 19). (b) Plasmatic VEGF was measured in patients with BDC below (low) and above (high) median value. (c) In HD, PDC express high levels of BDCA-4. In 44% of patients, 5-66% of PDC lack BDCA-4 at diagnosis. A normal BDCA-4 expression is restored after 3 months of IM. Data from one representative HD and patient (diag., IM/M3) are shown.
Blood dendritic cells in CML N Boissel et al functionally distinct, both DC types have the capacity to promote strong tumor-specific Th1 and cytotoxic T-cell (CTL) responses.
14 Our work shows a severe depletion of PDC and MDC in CP CML patients at diagnosis. A reduction in circulating DC has also been reported in multiple myeloma, acute myeloid leukemia and Sezary syndrome. [15] [16] [17] These data and our findings indicate that a loss of BDC is a feature shared by different hematologic malignancies and suggest that common mechanisms to defective DC populations exist. VEGF, an important regulator of angiogenesis and hematopoiesis, is secreted in large amounts by a wide variety of hematopoietic tumors. 18 In mice, VEGF infusion dramatically decreases DC production and injection of anti-VEGF antibodies significantly increases DC numbers in tumor-bearing animals. 12, 19 In humans, VEGF inhibits MDC differentiation from bone marrow precursors in vitro via inhibition of nuclear factor-kB (NF-kB) activation. 20 The action of VEGF on PDC differentiation has never been studied. However, VEGF induces activation of inhibitor of DNA binding (Id) proteins, 21 implicated in the development of PDC from CD34 þ progenitors. 22 Thus, VEGFmediated blockade of MDC and PDC production is likely to operate in patients, given the correlation we found between excessive plasmatic VEGF and low numbers of BDC in CML.
We were particularly interested in the analysis of PDC. These cells are indeed potent producers of type I interferon, a key cytokine for both innate and adaptative Th1 and CTL immunity. Moreover, type I IFN inhibits CML cell growth, 23 and was the first-line treatment of CML before the IM era. We showed that a substantial proportion of PDC lacked the VEGF-co receptor BDCA-4/NRP-1 molecule. Although the mechanisms involved are unknown, it is likely that defective BDCA-4/NRP-1 expression impairs PDC-induced T-cell responses in CML since BDCA-4/NRP-1 is essential to the establishment and function of the immunological synapse between DC and T cells. 8 At present, there is indirect indication that VEGF not only compromises DC production, but also impairs the function of differentiated immune cells. VEGF blockade improves endogenous DC function and enhances the efficacy of exogenous DC vaccines in tumor-bearing mice. 19 Our data show that VEGF decreases PDC-driven Th1 responses and favors Th2 responses in vitro and highlight a significant link between elevated plasmatic VEGF and low Th1/Th2 ratio in patients. VEGF overproduction may thus contribute to the Th2 deviation in CML and to defective antileukemic CTL responses. 3, 24 Upon IM administration, 100% of the patients entered complete hematologic remission and 90.4% of patients achieved complete or major cytogenetic responses. For the first time, we show in a large prospective cohort that despite a normalization of peripheral blood VEGF concentrations and a significant decrease of bcr-abl-positive hematopoiesis, patients responding to IM do not recover normal BDC rates and normal balance between Th1 and Th2 cells. IM does not solely target bcr-abl but also blocks phosphorylation of other tyrosine kinases such as c-kit, involved in the expansion of DC precursors. 25 In humans, IM was shown to inhibit the expansion of normal CD34 þ progenitor cells in vitro 26 and to impair the differentiation of normal CD34 þ precursors into myeloid DC. 27 In mice, IM was found to impair Flt3L-mediated DC expansion. 28 Our data and these experimental findings support a negative impact of IM on dendritopoiesis in vivo. Thus, a possible scenario is that IM initially increases BDC through inhibition of factors related to the leukemic process. After Ph1 À hematopoiesis is restored, IM compromises normal DC differentiation, explaining the incomplete recovery of BDC. It will be important to determine the Ph1 status of PDC and MDC at diagnosis and upon remission in order to dissect the effects of IM on dendritopoïesis at different stages of the disease.
Although IM constitutes a major breakthrough in the control of CML, patients rarely achieve complete molecular responses. 29 Our findings may be clinically relevant since incomplete recovery of BDC under IM therapy could compromise long-term immune-mediated control of this disease. Thus, combining bcr-abl-directed molecules with strategies designed to reconstitute an intact DC network in vivo /IL-4 þ ) polarization was assessed by intracellular cytokine staining after stimulation with PMA and ionomycin. Th1/Th2 ratios from five independent experiments are shown. (b) Th-cell polarization was analyzed in six HD and in 14 patients at diagnosis (diag.) and after 6 months of IM. PBMC were stimulated with PMA and ionomycin and T-cell polarization was assessed as above. Th1/Th2 ratios are shown. (c) Plasmatic VEGF was compared between patients with Th1/ Th2 ratios below (low) and above (high) median value.
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N Boissel et al may be required to achieve leukemic eradication in CML patients.
